张天英
教授
电子邮箱:zhangtianying@xmu.edu.cn
教育经历:
2011/09-2016/06,厦门大学生命科学学院,生物化学与分子生物学专业,博士
2007/09-2011/06,厦门大学生命科学学院,生物技术专业,学士
科研与学术工作经历
2022/08-至今 厦门大学公共卫生学院,副教授
2020/01-2022/07 厦门大学公共卫生学院,助理教授
2017/11-2018/11 美国Scripps研究所,Professional Scientific Collaborator
2016/07-2019/12 厦门大学公共卫生学院,博士后
主要研究方向:
1. 乙肝治疗性抗体与治疗性疫苗;
2. 呼吸道黏膜疫苗与免疫机制;
3. 新型佐剂、VSV病毒载体等疫苗免疫增强技术;
4. 免疫治疗新靶标与抗体药物研发。
原创发现乙肝治疗独特靶点,发明了基于该靶点的候选治疗性抗体与治疗性疫苗,揭示了抗体识别表位-抗原/抗体复合物尺寸-抗体治疗效力之间的关系,候选治疗性抗体进入临床试验。拓展呼吸道黏膜疫苗免疫理论,助力鼻喷广谱新冠疫苗研发并获批紧急使用。近年发表论文40余篇,其中以第一作者/通讯作者(含共同)在Gut、Nature Communications、PNAS、Lancet Respiratory Medicine、Cell Host & Microbe等期刊发表研究论文20余篇,H指数23,总被引>4800次;国内外专利授权25件;获得国家自然科学基金面上项目/青年项目/重大项目(任务级)、福建省杰出青年基金、福建省拔尖人才计划、南强青年拔尖人才计划支持。
学术论文(共同第一/通讯作者):
(1) Zhang TY#, Guo XR#, Wu YT#, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020 Feb,69(2):343-354.
(2) Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Li TL, Kang XZ, Zhao JH, Yin B, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of the Hepatitis B virus X protein BH3-like domain and its interaction with Bcl-xL. Nature Communications. 2019, 10:3192.
(3) Zhang TY#, Yuan Q#,*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JW, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*, Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen, Gut, 2016, 65(4): 658-71.
(4) Xiong HL#, Sun H#, Wang SL#, Yuan LZ#, Liu LQ#, Zhu YH#, Zhang JL#, Huang Y, Qi RY, Jiang Y, Ma J, Zhou M, Ma Y, Fu R, Yan SP, Yue MX, Wu YT, Wei M, Wang YZ, Li TT, Wang YB, Zheng ZZ, Yu H, Cheng T, Li SW*, Yuan Q*, Zhang J*, Guan Y*, Zheng QB*, Zhang TY*, Xia NS*. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Proc Natl Acad Sci USA, 2022, 119(34): e2204256119.
(5) Xiong HL#, Wu YT#, Cao JL#, Yang R#, Liu YX#, Ma J, Qiao XY, Yao XY, Zhang BH, Zhang YL, Hou WH, Shi Y, Xu JJ, Zhang L, Wang SJ, Fu BR, Yang T, Ge SX, Zhang J, Yuan Q, Huang BY*, Li ZY*, Zhang TY*, Xia NS*. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect. 2020 Dec,9(1):2105-2113.
(6) Zhu FC#, Zhuang CL#, Chu K#, Zhang L#, Zhao H#, Huang SJ, Su YY, Lin HY, Yang CL, Jiang HM, Zang X, Liu DL, Pan HX, Hu YM, Liu XH, Chen Q, Song QQ, Quan JL, Huang ZH, Zhong GH, Chen JY, Han YL, Sun H, Cui LB, Li JX, Chen YX*, Zhang TY*, Ye XZ*, Li CG*, Wu T*, Zhang J*, Xia NS*, Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials, The Lancet Respiratory Medicine, 2022, 10(8): 749-760
(7) Wu YT#, Wang SJ#, Zhang YL#, Yuan LZ#, Zheng QB#, Wei M#, Shi Y#, Wang ZK, Ma J, Wang K, Nie MF, Xiao J, Huang ZH, Chen PW, Guo HL, Lan ML , Xu JJ, Hou WH, Hong YD, Chen DB, Sun H, Xiong HL, Zhou M, Liu C, Guo WJ, Guo HY, Gao JH, Gan CL, Li ZX, Zhang HT, Wang XR, Li SW, Cheng T, Zhao QJ, Chen YX, Wu T, Zhang TY*, Zhang J*, Cao H*, Zhu HC*, Yuan Q*, Guan Y*, Xia, N.*. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. Cell Host & Microbe, 2022, 30(12): 1732-1744 e7.
(8) Lu J#, Lu GL#, Tan SD#, Xia J#, Xiong HL#, Yu XF#, Qi QQ, Yu X, Li L, Yu H, Xia NS, Zhang TY*, Xu YJ*, Lin JZ*. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020 Oct,30(10):936-939.
(9) Wu YT#, Huang XF#, Yuan LZ#, Wang SJ#, Zhang YL#, Xiong HL#, Chen RR, Ma J, Qi RY, Nie MF, Xu JJ, Zhang ZG, Chen LQ, Wei M, Zhou M, Cai MP, Shi Y, Zhang L, Yu H, Hong JP, Wang ZK, Hong YD, Yue MX, Li ZL, Chen DB, Zheng QB, Li SW, Chen YX, Cheng T, Zhang J*, Zhang TY*, Zhu HC*, Zhao QJ*, Yuan Q*, Guan Y*, Xia NS*. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Science Translational Medicine, 2021, 13(606): 1-15
(10) Chen JY#, Wang P#, Yuan LZ#, Zhang L#, Zhang LM#, Zhao H#, Chen CJ#, Wang XJ#, Han JL#, Chen YD#, Jia JZ, Lu Z, Hong JP, Lu ZC, Wang Q, Chen RR, Qi RY, Ma J, Zhou M, Yu H, Zhuang CL, Liu XH, Han QY, Wang GS, Su YY, Yuan Q, Cheng T, Wu T, Ye XZ, Zhang TY*, Li CG*, Zhang J*, Zhu HC*, Chen YX*, Chen HL*, Xia NS*. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin, 2022, 67 (13) ,1372-1387
(11) Wang SL#, Sun H#, Zhang YL#, Yuan YZ#, Wang YZ#, Zhang TY#, Wang SJ, Zhang JL, Yu H, Xiong HL, Tang ZM, Liu LQ, Huang Y, Chen XT, Li TT, Ying D, Liu C, Chen ZH, Yuan Q, Zhang J*, Cheng T*, Li SW*, Guan Y*, Zheng QB*, Zheng ZZ*, Xia NS*. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Reports, 2022, 39(8): 110862.
(12) Zhou B#, Xia L#, Zhang TY#, You M, Huang Y, He MZ, Su RP, Tang JX, Zhang J, Li SW, An ZQ, Yuan Q*, Luo WX*, Xia NS*, Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development, Antiviral Research, 2020, 180:104757.
(13) Xiong HL#, Cao JL#, Shen CG#, Ma J, Qiao XY, Shi TS, Ge SX, Ye HM, Zhang J, Yuan Q*, Zhang TY*, Xia NS*, Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro, Frontiers in Pharmacology, 2021, 11(2516)
(14) Wang SL#, Wu DH#, Xiong HL#, Wang J#, Tang ZM, Chen ZH, Wang YZ, Zhang YL, Ying D, Lin X, Liu C, Guo SQ, Tian WK, Lin YJ, Zhang XP, Yuan Q, Yu H, Zhang TY*, Zheng ZZ*, Xia NS*, Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines, Frontiers in Immunology, 2022, 13
(15) Zhang ZG#, Zhang TY#, Cao L#, Wang X, Cao JL, Huang XF, Cai YS, Lin ZJ, Pan HR, Yuan Q, Fang MJ, Li SW, Zhang J, Xia NS, Zhao QJ*. Simultaneous in situ visualization and quantitation of dual antigens adsorbed on adjuvants using high content analysis. Nanomedicine. 2019 Oct,14(19):2535-2548.
(16) Li J#, Zhang TY#, Song LW, Qi X, Yu XP, Li FH, Zhou P, Qin YL, Yang L, Zhao JH, Mao RC, Zhang YM, Wang JY, Yang FF, Zhu HX, Yang SS, Huang YX, Yuan Q*, Zhang J, Zhang JM*, Xia NS. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels, Hepatol Res., 2018, 48(3): E133-E145.
(17) Kang XZ#, Guo XR#, Chen BB, Zhang TY*, Yuan Q*, Chen PJ, Zhang J, Xia NS. The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice, Human vaccines & immunotherapeutics, 2018, 13: 1-3.
授权发明专利(共25件授权):
1. 张天英,袁权,郭雪染,张莹,赵勤俭,张军,夏宁邵,一种用于展示目的多肽的多肽载体及其用途。获中、美、欧、日等12件授权。
2. 袁权,张天英,罗文新,陈毅歆,张军,夏宁邵,用于治疗HBV感染及相关疾病的多肽及抗体。获中、美、欧、日等12件授权。
3. 曹佳莉,袁权,张天英,赵菁华,张军,夏宁邵,一种检测系统。获中国专利授权。
受理发明专利(9项专利,4项PCT):
1. 张天英,袁权,郭雪染,康晓圳、张军、夏宁邵,一种用于展示目的多肽的多肽载体及其用途。中国专利申请日:2018.2.5,申请号:201810110910.3;国际专利申请日:2018.2.14,申请号:PCT/CN2018/075199。
2. 张天英,曹佳莉,施恬树,马建,王邵娟,袁权,张军,夏宁邵,Palovarotene在抗HBV病毒治疗中的用途。中国专利申请日:2020.6.12, 申请号:202010531845.9。
3. 张天英、熊华龙、朱雨荷、张金蕾、江尧、颜思平、袁伦志、罗文新、袁权、张军、夏宁邵,针对冠状病毒的抗体及其用途。申请号:202210196184.8.
4. 袁权,张天英,罗文新,陈毅歆,张军,夏宁邵,用于治疗HBV感染及相关疾病的多肽及抗体。中国专利申请日:2013.6.6,申请号:201310222728.4;国际专利申请日:2013.6.6,申请号:PCT/CN2013076832。
5. 罗文新,康赐明,王一文,袁权,张天英,夏宁邵,用于治疗乙肝感染及相关疾病的抗体。中国专利申请日:2017.4.7,申请号:201710223992.8;国际专利申请日:2018.4.20,申请号:PCT/CN2018/082157。
6. 罗文新,周兵,张娟,袁权,张天英,张军,夏宁邵,抗乙肝表面抗原的人源化抗体及其用途。中国专利申请日:2016.10.10,申请号:201610879693.5;国际专利申请日:2016.10.9,申请号:PCT/CN2016/101560。
7. 罗文新、王一文、康赐明、袁权、张天英、夏宁邵,用于治疗乙肝感染及相关疾病的抗体。中国专利申请日:2018.4.8,申请号: 201810307136.5 。
8. 袁权、巫洋涛、熊华龙、张天英、王邵娟、蒋艺超、侯汪衡、施洋、张雅丽、罗文新、夏宁邵,针对SARS-CoV-1或SARS-CoV-2的抗体及其用途。中国专利申请日:2020.5.6,申请号: 202010369877.3。
9. 张雅丽、王邵娟、巫洋涛、侯汪衡、叶江辉、王娟、张天英、程通、袁权、夏宁邵,用于筛选冠状病毒感染阻断剂的检测试剂及检测方法。中国专利申请日:2020.5.6,申请号: 202010365755.7。
主持或参加科研项目情况:
(1) 福建省杰出青年科学基金项目,β属冠状病毒B亚群广谱中和表位鉴定及其在疫苗和抗体研发中的应用,2020-08至2023-08,在研,主持
(2) 国家自然科学基金面上项目,基于新型双膦酸盐佐剂和表位嵌合颗粒抗原的乙肝治疗性疫苗疗效与机制研究,2022-01至2025-12,在研,主持
(3) 国家自然科学基金重大项目,保护性体液免疫形成及维持机制,2020-01至2024-12,在研,主持
(4) 国家自然科学基金青年项目,慢性乙肝病人基线血清HBV感染力与治疗应答的相关性及其病毒学机制研究, 2018/1-2020/12, 已结题, 主持
(5) 国家基金重点项目,多聚化抗原诱导高效体液免疫应答的机制研究, 2018/1-2022/12,已结题, 课题骨干
(6) 中国博士后科学基金面上资助,基于独特表位的慢性乙型肝炎治疗性抗体作用机制研究, 2016/7-2019/7, 8.00万元, 已结题, 主持
(7) 厦门市青年创新基金项目,针对慢性乙型肝炎的候选治疗性抗体免疫效应机制研究,2020-07至2023-06,在研,主持
(8) 横向项目,重组新型冠状病毒疫苗(CHO细胞)免疫原的研发,2020-01至 2021-12,已结题, 主持